Physician profile
Melissa Mclean
NPI 1427712397
$897.50
in general payments reported to CMS, 2019-2025
11 companies · $66.84 in 2025
The $66.84 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $67.57 · 2023: $283 · 2024: $480 · 2025: $66.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.94 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $394.30 | 2023-2025 | Enhertu |
| Ipsen Biopharmaceuticals, INC | $113.49 | 2023 | Onivyde, Somatuline Depot |
| Gilead Sciences, INC. | $111.99 | 2024 | |
| Janssen Biotech, INC. | $61.93 | 2024 | Tecvayli, Talvey, Darzalex |
| Coherus Oncology, INC. | $41.85 | 2024 | |
| Amgen INC. | $33.96 | 2022 | |
| Genzyme Corporation | $33.61 | 2022 | |
| Merck Sharp & Dohme LLC | $33.28 | 2023 | Keytruda |
| Urogen Pharma, INC. | $30.33 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $22.17 | 2023 | |
| Genmab U.S., INC. | $20.59 | 2025 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Mclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.